Similarly, the identification of aberrant signalling downstream of (Epidermal growth factor receptor) EGFR mutation and (Receptor tyrosine-protein kinase erbB-2) Her2 amplification opened new therapeutic windows in lung, breast and colon cancer [27,28]. Here, EGFR is linked to malignant colon neoplasm.